Last reviewed · How we verify

An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT04825626 NO_LONGER_AVAILABLE

This is an Individual Patient Expanded Access IND to evaluate the safety and preliminary efficacy of autologous HB-adMSCs for treating a single patient Chronic Inflammatory Demyelinating Polyneuropathy, CIDP. The expanded access program will include a screening period of up to 28 days, a 44-week treatment period, a safety follow-up at 50, and a 52-week end-of-study visit.

Details

Lead sponsorHope Biosciences Research Foundation
StatusNO_LONGER_AVAILABLE

Conditions

Interventions

Countries

United States